Johnson & Johnson (NY:JNJ)

202.72 +0.79 (+0.39%)

Streaming Delayed Price Updated: 10:25 AM EST, Dec 8, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Kenvue (KVUE) Plunges Amidst Dual Headwinds: Tylenol Fears and Escalating Talc Litigation

October 16, 2025

Kenvue (NYSE: KVUE), the consumer health giant spun off from Johnson & Johnson, has found itself at the bottom of today's market performance, with its stock price experiencing a significant decline. As...

Via MarketMinute

Topics Government Lawsuit

Investors Retreat to Safety: US Fund Flows Signal Defensive Stance Amidst Market Uncertainty

October 16, 2025

As October 2025 progresses, a palpable shift in investor sentiment is evident across US financial markets, with recent fund flow data signaling a clear pivot towards defensive strategies. Faced with...

Via MarketMinute

Topics Bonds Economy

Johnson & Johnson Reports Strong Phase 3 Results For Multiple Myeloma Therapy ↗

October 16, 2025

Tecvayli combined with Darzalex Faspro improves overall survival in relapsed/refractory multiple myeloma, Johnson & Johnson reports.

Via Benzinga

Johnson & Johnson: Earnings Beat, High Technical Momentum, UK Talc Suits Loom ↗

October 16, 2025

Johnson & Johnson's stock shows strong technical momentum following a modest earnings beat, but faces potential volatility due to ongoing UK talc lawsuits and a strategic orthopedics spinoff.

Via Talk Markets

Topics Earnings Lawsuit

Jamison Loads Up on Johnson & Johnson (JNJ) Stock With a 39K Share Purchase ↗

October 16, 2025

Via The Motley Fool

Topics Regulatory Compliance

Johnson & Johnson, Kenvue Named In First Ever UK Legal Action Over Talc Cancer Claims ↗

October 16, 2025

Johnson & Johnson faces 3,000 UK lawsuits alleging asbestos-contaminated talcum powder caused cancer and concealed risks for decades.

Via Benzinga

Topics Lawsuit

Johnson & Johnson Reportedly Faces Major UK Lawsuit Over Baby Powder Cancer Risks ↗

October 16, 2025

A legal claim involving 3,000 people has been reportedly filed against Johnson & Johnson (NYSE: JNJ) in the U.K., alleging that the company knowingly sold asbestos-contaminated baby powder.

Via Benzinga

Topics Lawsuit

Scott Bessent Says US Investment Boom 'Sustainable' Under Trump: 'The Only Thing Slowing Us Down...' ↗

October 16, 2025

U.S. Treasury Secretary Scott Bessent credited the country's investment boom to President Donald Trump's policies on Wednesday, and expressed optimism about its sustainability, but said the government...

Via Benzinga

Topics Government

Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever. ↗

October 16, 2025

Investors should be able to count on these stocks to deliver steady and growing income over the long term.

Via The Motley Fool

Johnson & Johnson Battles New UK Talc Cancer Claims Worth £1B After Massive US Verdict: Report ↗

October 15, 2025

Meanwhile, analysts raised price targets on the stock following strong Q3 results and the planned orthopedic spin-off.

Via Stocktwits

Topics Bankruptcy Death Lawsuit

Dow Jones Stumbles with Fractional Dip, Signaling Cautious Market Sentiment Amidst Global Headwinds

October 15, 2025

New York, NY – October 15, 2025 – The Dow Jones Industrial Average (DJIA) experienced a fractional dip today, reflecting a palpable sense of caution pervading market sentiment. While other major...

Via MarketMinute

Topics Artificial Intelligence Economy Government

Dow Jones Stumbles Amidst Global Headwinds, Reflecting Cautious Market Sentiment

October 15, 2025

The Dow Jones Industrial Average (DJIA) concluded a volatile trading day on Wednesday, October 15, 2025, with a fractional dip, signaling a cautious, if not overtly negative, sentiment pervading the...

Via MarketMinute

Topics Artificial Intelligence Bonds Climate Change

Dividend Defenders: How Two Stalwart Stocks Weathered April's Market Squall

October 15, 2025

As the calendar turned to April 2025, financial markets found themselves in a precarious position, teetering on the brink of a full-blown bear market. Investor fears, fueled by persistent inflation,...

Via MarketMinute

Topics Bonds Economy Energy

Dividend Duo Delights Investors: Meta Platforms and Johnson & Johnson Shine in 2025

October 15, 2025

In a year marked by evolving market dynamics and a persistent search for both growth and stability, two distinct titans of industry—Meta Platforms (NASDAQ: META) and Johnson & Johnson (NYSE: JNJ)—have...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

These Analysts Boost Their Forecasts On Johnson & Johnson After Upbeat Q3 Earnings ↗

October 15, 2025

Via Benzinga

Wall Street's Earnings Momentum Fades, Market Dips Amidst Trade Tensions

October 15, 2025

Wall Street witnessed a significant shift this Wednesday as an eagerly anticipated earnings push ultimately petered out, sending stocks into the red. This downturn followed a volatile Tuesday, which...

Via MarketMinute

Topics Economy Supply Chain World Trade

Johnson & Johnson Rules Out Big Acquisitions, Reiterates Focus On Small Deals: Analyst ↗

October 15, 2025

Johnson & Johnson raised its 2025 revenue guidance as Stelara erosion slowed, while BofA maintained a Neutral rating citing fair valuation.

Via Benzinga

2 Dividend Stocks I'm Very Thankful I Owned This Year ↗

October 15, 2025

I don't intend to sell my shares of these companies anytime soon.

Via The Motley Fool

Topics Artificial Intelligence Economy Government

Johnson & Johnson Stock Can Keep Rising as Strategy Pays Off ↗

October 15, 2025

Johnson & Johnson (NYSE: JNJ) beat Q3 estimates, raised revenue guidance, and plans an orthopedics spin-off—analysts see up to 50% upside for JNJ stock.

Via MarketBeat

New Jersey Rep. Thomas Kean Sold Up to $215K Worth of Franklin Resources Stock ↗

October 15, 2025

Via Benzinga

2 Ultra-High-Yield Dividend Stocks With Total Return Potential of Up to 41% in 12 Months, According to Select Wall Street Analysts ↗

October 15, 2025

Juicy dividends are only part of the attraction with these beaten-down stocks.

Via The Motley Fool

Topics Government

This 2.7%-Yielding Dividend King Remains One of the Healthiest Income Stocks You Can Buy ↗

October 15, 2025

Johnson & Johnson has a very healthy financial profile and growth prospects.

Via The Motley Fool

Topics Bonds

Powell Calms the Markets While Trade Tensions Keep Investors on Edge ↗

October 15, 2025

A dovish tone from Fed Chair Jerome Powell helped Wall Street recover from early losses, but U.S.–China tensions under President Trump’s renewed tariff threats kept sentiment fragile. Strong bank...

Via Chartmill

Topics Economy Government World Trade

AI Revolutionizes Quality Control: A New Era of Precision and Speed in Manufacturing, Electronics, and Pharmaceuticals

October 14, 2025

A groundbreaking wave of Artificial Intelligence (AI) tools is poised to fundamentally transform materials quality checking, ushering in an era of unparalleled precision, speed, and cost-efficiency...

Via MarketMinute

Topics Artificial Intelligence Economy Fraud

Looking At Johnson & Johnson's Recent Unusual Options Activity ↗

October 14, 2025

Via Benzinga

The Gathering Storm: AI Overbuilding, Trade Wars, and National Debt Fuel Market Crash Fears

October 14, 2025

As of October 14, 2025, a palpable sense of unease permeates global financial markets, with a growing chorus of analysts and institutions warning of a potential market crash. The prevailing sentiment...

Via MarketMinute

Topics Artificial Intelligence Bonds Economy

Johnson & Johnson To Spin Off Orthopedics Unit After Raising 2025 Sales Forecast ↗

October 14, 2025

Johnson & Johnson on Tuesday lifted its 2025 revenue guidance after posting stronger-than-expected third-quarter earnings.

Via Talk Markets

S&P Drug Titan J&J Dips After Announcing A Surprise Spinoff ↗

October 14, 2025

The news comes alongside a third-quarter beat and sales guidance hike.

Via Investor's Business Daily

Topics Stocks

Johnson & Johnson To Separate Orthopedics Business, Boosts Annual Sales Outlook ↗

October 14, 2025

Johnson & Johnson beats Q3 estimates, raises 2025 sales guidance, and announces plans to spin off its $9.2 billion orthopedics business, DePuy Synthes.

Via Benzinga

Johnson & Johnson (NYSE:JNJ) Beats Q3 2025 Estimates and Raises Full-Year Sales Outlook ↗

October 14, 2025

Johnson & Johnson (JNJ) beat Q3 2025 earnings estimates, raised its full-year sales outlook, and announced a planned spin-off of its Orthopedics business.

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.